Innovative SDDS Position Pharmaco-Kinesis as a provider of proprietary local Smart Drug Delivery Systems and diagnostic-enabled devices, with the Metronomic Biofeedback Pump as a flagship offering for local, programmable tumor therapy. Target healthcare providers and research centers focusing on leptomeningeal carcinomatosis and brain cancers seeking advanced localized treatment options.

Strategic IP Emphasize a growing patent portfolio and tech pipeline including VEGF BioSensor and Intelligent Interbody Fusion Device to prospective partners and licensees, highlighting potential cross-application opportunities in oncology, spine surgery, and tissue regeneration.

Early-Stage Growth Leverage the company’s early-stage, high-technology profile and recent funding to engage venture-backed hospitals, academic medical centers, and biotech collaborations that invest in disruptive medical devices and local therapy platforms.

Clinical Focus Highlight the MBP’s potential to significantly advance brain cancer and leptomeningeal disease treatment, aligning with clinical trial interest and institutional partnerships seeking innovative delivery mechanisms with remote programmability and real-time therapy modulation.

Affordability Signals With current revenue in the low-to-mid multi-million range and modest funding, pursue scalable partnerships and pilot programs with larger pharma and medical device landscape players for co-development, validation studies, and, eventually, larger-scale commercialization.